[go: up one dir, main page]

WO2014065545A1 - Composition pharmaceutique contenant de la lobarstine pour prévenir ou traiter une tumeur cérébrale et polythérapie pour le traitement d'une tumeur cérébrale l'utilisant - Google Patents

Composition pharmaceutique contenant de la lobarstine pour prévenir ou traiter une tumeur cérébrale et polythérapie pour le traitement d'une tumeur cérébrale l'utilisant Download PDF

Info

Publication number
WO2014065545A1
WO2014065545A1 PCT/KR2013/009366 KR2013009366W WO2014065545A1 WO 2014065545 A1 WO2014065545 A1 WO 2014065545A1 KR 2013009366 W KR2013009366 W KR 2013009366W WO 2014065545 A1 WO2014065545 A1 WO 2014065545A1
Authority
WO
WIPO (PCT)
Prior art keywords
present
lovastin
brain cancer
tmz
temozolomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/009366
Other languages
English (en)
Korean (ko)
Inventor
임정한
김일찬
김덕규
한세종
정희경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Ocean Science and Technology KIOST
Original Assignee
Korea Institute of Ocean Science and Technology KIOST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Ocean Science and Technology KIOST filed Critical Korea Institute of Ocean Science and Technology KIOST
Publication of WO2014065545A1 publication Critical patent/WO2014065545A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a novel use of the natural product-derived metabolite, lovastin, and more particularly, to the prophylaxis or treatment of brain cancer containing lovastin or a pharmaceutically acceptable salt thereof and with temozolomide for the treatment of brain cancer. It relates to the use to combination therapy.
  • Lichens are known to produce higher plants and other unique secondary metabolites (Ingolfsdottir, K., Phytochemistry , 61: 729, 2002), and most of the secondary metabolites they produce are depside and depsidone. And dibenzfurane, which compounds are believed to be associated with the low growth rate of lichens (Kumar, KCS et al., J. Nat. Prod ., 62: 817, 1999; Huneck, S.
  • glioblastoma multiforme is a malignant carcinoma originating from glial cells and their progenitor cells of the central nervous system and most often occurs in the subcortical white matter of the cerebral hemispheres in the cortical temporal lobe of the brain.
  • GBM is the most aggressive of the glioblastomas with a poor prognosis (S. Tanaka et al., Nat Rev Clin Oncol , 10: 14-26, 2013).
  • GBM corresponds to Grade IV among glial-derived carcinomas, with a high cell count, active cell division, and associated with vascular proliferation and necrosis (AJCC cancer staging handbook: from the AJCC cancer staging manual.7th ed. 2010, New York: Springer. Xix, 718 p).
  • GBM Surgical surgical removal of GBM is a standard treatment that combines radiotherapy with chemotherapy but is a very deadly carcinoma with an average survival rate of only 14.6 months (N. Engl. J. Med. (2005) 3520: 987 ). GBM has a very high recurrence rate, with very poor prognosis with 15-21% of 6-month progression-free survival (PFS) and 25 weeks of average survival (J. Clin. Oncol. (1999) 17: 2572).
  • PFS 6-month progression-free survival
  • Temozolomide a drug used in the standard treatment of GBM, is an alkylating agent that causes DNA damage to remove cancer cells (Lancet (2000) 355: 1115). This produces a variety of methyl adducts at the O 6 -guanine, N 7 -guanine and N 3 -guanine positions on DNA (JNSarkaria et al., Clin Cancer Res , 14: 2900-8, 2008). Higher expression of the DNA repair gene 0 6 -methylguanine-DNA-methyltransferase (MGMT) or a transporter (eg P-glycoprotein) that regulates the drug's intracellular bioavailability (J. Neurochem. (2006) 96: 766; Acta. Neuropathol.
  • MGMT DNA repair gene 0 6 -methylguanine-DNA-methyltransferase
  • transporter eg P-glycoprotein
  • TMZ Cytotoxicity of TMZ depends on DNA repair systems such as mismatch repair (MMR), MGMT repair and base excision repair (BER) (M. Grzmil et al., Biochim Biophys Acta , 1834: 1371-80, 2013; M. Nakada et al., Front Oncol , 2:98, 2012; J. Koritzer et al., PLoS One 8 , e64498, 2013).
  • MMR mismatch repair
  • BER base excision repair
  • GBM exhibits a complex pattern including a wide variety of genetic mutations, including p53 deletion, overexpression of EGFR and VEGF, and gene amplification of MDM2 and MGMT (US Pharmacist. (2010) 35: 3; J; Neurooncol. (2010) 96: 169).
  • overexpression of the MGMT gene is highly correlated with resistance to TMZ (J. Neurochem. (2006) 96: 766). Therefore, there is a need for the development of therapies that can enhance the effectiveness of current standard therapies.
  • the present inventors have sought to provide a new substance that is effective in eliminating temozolomide-resistant cancer cells and can enhance brain cancer treatment effects when co-administered with temozolomide.
  • lovastin according to the present invention alone prevents brain cancer. And not only can be treated, it was confirmed that the anti-cancer effect is enhanced when combined with the anticancer temozolomide used in the standard therapy of brain cancer, the present invention was completed.
  • An object of the present invention is to provide a new material capable of preventing and treating brain cancer.
  • Another object of the present invention is to provide a new usage that can enhance the effectiveness of the standard treatment of current brain cancer.
  • the present invention provides a method of enhancing the toxic effect of an existing anticancer agent through a combination treatment with an anticancer agent, temozolomide (TMZ), which is used in the standard therapy of brain cancer.
  • TTZ temozolomide
  • the present invention provides a new use of a natural product-derived metabolite to prepare a drug that can overcome the anticancer drug resistance.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of brain cancer containing a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
  • the present invention also provides a combination therapy of co-administering the pharmaceutical composition with temozolomide (TMZ).
  • TMZ temozolomide
  • the present invention also provides the use of a compound represented by the following formula (1) for the manufacture of a medicament for the prevention or treatment of brain cancer:
  • the present invention also provides a functional food for the prevention or improvement of brain cancer containing the compound represented by the following formula (1) or a food acceptable salt thereof as an active ingredient:
  • the present invention also provides a combination therapy in which the functional food is co-administered with temozolomide (TMZ).
  • TTZ temozolomide
  • 1 is a graph showing the anticancer effect of the compound of Formula 1, namely, lovastin's T98G cell line, which is a temozolomide-resistant polymorphic glioblastoma cell line, wherein 1A is a graph showing cytotoxicity according to the concentration of temozolomide against T98G cell line. And 1B is a graph showing the cytotoxicity according to the concentration of the compound of formula 1, ie lovastin, against the T98G cell line.
  • Figure 2 shows the cell viability of normal cells and T98G cells according to lovastin treatment of Example 3-2, that is, a graph showing the cytotoxicity according to the concentration of lovastin.
  • Figure 3 is a graph comparing the cytotoxicity of T98G cell line with high concentration of TMZ (750 ⁇ M) and 40 ⁇ M lovastin of the present invention alone and combined treatment (Robarstin + TMZ) for 3 days and 4 days, respectively.
  • Figure 4 is a graph comparing the cytotoxicity of the T98G cell line with low concentration of TMZ (500 ⁇ M) and 40 ⁇ M lovastin of the present invention alone and combined treatment (Robarstin + TMZ) for 3 days and 4 days, respectively.
  • Figure 5 shows the expression of MGMT and GAPDH of T98G cells of Example 5-4.
  • FIG. 6 shows cell viability when lovastin and TMZ are used in combination with the concentration of TMZ of Example 5-4, and shows the results of treatment for 3 days and 4 days.
  • Example 7 shows cell viability when lovastin and TMZ are used in combination with the concentration of TMZ of Example 5-4, where V is a vehicle-administered group and L is a lovastin-administered group.
  • Figure 8 shows the recovery of TMZ induced DNA damage by lovastin of Example 5-5
  • A shows the time conditions of DNA damage and DNA repair
  • B image obtained by fluorescence microscopy
  • C shows the numerical results of the experiment.
  • V is a vehicle administration group
  • L is a lovastin administration group
  • T is a TMZ administration group
  • LT is a lovastin and TMZ administration group
  • D means damage
  • R means repair.
  • Figure 9 shows the decrease in the expression of MGMT, PARP1, etc. when lovastin is administered for 2 days through the immunoblot (Immunoblot) results of Examples 5-6 (left), MGMT, PARP1 through RT-PCR results Decrease in expression of the back (right).
  • V means vehicle administration group
  • L means lovastin administration group.
  • Figure 10 shows the decrease in expression of MGMT, PARP1, etc. through the immunoblot (Immunoblot) results of Example 5-6.
  • V is a vehicle administration group
  • L is a lovastin administration group
  • T is a TMZ administration group
  • LT is a lovastin and TMZ administration group
  • D means damage
  • R means repair.
  • FIG. 11 shows the reduced expression of DNA repair genes in cells using lovastin and TMZ.
  • “Co-administration” herein may be achieved by the simultaneous, sequential or separate administration of the individual components of the therapy.
  • the combination therapy is, for example, the degree of response, reaction rate, disease progression Efficacy as measured over a period of time or survival is defined as being capable of providing a synergistic effect while being therapeutically superior to the efficacy obtained by administering one or the other of the components of the combination therapy in conventional dosages.
  • the compound of formula 1 of the present invention may be administered before, after, or simultaneously with administering an effective amount of temozolomide.
  • the anticancer efficacy of the treatment method of the present invention includes, but is not limited to, antitumor efficacy, response rate, duration to disease progression, survival rate, and the like.
  • Antitumor efficacy of the treatment methods of the present invention includes, but is not limited to, tumor growth inhibition, tumor growth delay, tumor regression, tumor shrinkage, increased duration to tumor regrowth upon discontinuation of treatment, delay in disease progression, and the like.
  • the methods of treatment are measured, for example, by one or more of the degree of antitumor efficacy, response rate, duration to disease progression, and survival rate. It is expected to produce a potent efficacy.
  • Anticancer efficacy includes prophylactic treatment as well as treatment of existing diseases.
  • an "extract" of lichens is a substance obtained by dissolving an individual, tissue, or cell of lichens in a solvent, and may be concentrated by distillation or evaporation.
  • the present invention relates to a pharmaceutical composition for preventing or treating brain cancer containing, as an active ingredient, a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof in one aspect:
  • a cell proliferation assay is performed after treatment of lovastin, a compound of the natural product-derived metabolite 1, at various concentrations in a T98G cell line, a GBM cell line resistant to anti-cancer drug temozolomide (TMZ).
  • lovastin a compound of the natural product-derived metabolite 1
  • the lovastin concentration dependent apoptosis effect was assayed.
  • the concentration of lovastin showing apoptosis similar to that of high concentration of TMZ was determined.
  • the compound of Formula 1 of the present invention namely, lovastin is 50 ⁇ M or more toxic to T98G cell line, which is a TMM resistant GBM cell line. Remarkable was confirmed.
  • the cell death effects of TMZ-resistant GBM cell line T98G against TMZ were assayed through cell proliferation assay to establish conditions that induce cell death in a dose-dependent manner.
  • lovastin according to the present invention can be used alone as an effective drug for the prevention and treatment of brain cancer, but also at low concentrations, especially against brain cancer cell lines having temozolomide resistance, which is currently the only standard therapeutic anticancer agent for brain cancer. Bar suggests that it can be prepared as a drug that can overcome the anticancer drug resistance.
  • the inventors of the present invention use the compound of Formula 1 in combination with temozolomide, a standard therapy anticancer agent for brain cancer, than the case of using either the compound of Formula 1 or temozolomide alone. It has been found that it can provide significantly better efficacy. Accordingly, the present invention also provides a combination therapy of co-administering the pharmaceutical composition with temozolomide (TMZ). Wherein lovastin or a pharmaceutically acceptable salt thereof and temozolomide, respectively, may optionally be administered with a pharmaceutically acceptable excipient or carrier.
  • TMZ temozolomide
  • MGMT in combination with a natural product-derived metabolite lovastin in combination with TMZ to GBM cell line T98G resistant to the anticancer drug TMZ of the standard therapy to determine the cell death effect through cell proliferation assay It was confirmed that apoptosis was enhanced when combined with TMZ rather than monotherapy.
  • TMZ which is an anticancer agent of standard therapy
  • the compound of Formula 1, ie lovastin, used in the present invention may be in the form of a pharmaceutically acceptable salt.
  • Pharmaceutically acceptable salts in the present invention can be prepared by conventional methods in the art, for example, salts with inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid, sodium hydrogen sulfate, phosphoric acid, carbonic acid, and the like.
  • a pharmaceutically acceptable acid together with an organic acid such as formic acid, acetic acid, oxalic acid, benzoic acid, citric acid, tartaric acid, gluconic acid, gestyic acid, fumaric acid, lactobionic acid, salicylic acid, or acetylsalicylic acid (aspirin) Salts may be formed, or they may be reacted with alkali metal ions such as sodium or potassium to form their metal salts, or may be reacted with ammonium ions to form another form of a pharmaceutically acceptable salt.
  • an organic acid such as formic acid, acetic acid, oxalic acid, benzoic acid, citric acid, tartaric acid, gluconic acid, gestyic acid, fumaric acid, lactobionic acid, salicylic acid, or acetylsalicylic acid (aspirin) Salts may be formed, or they may be reacted with alkali metal ions such as sodium or potassium to form their metal salt
  • compositions comprising a compound according to the present invention or a pharmaceutically acceptable salt thereof are oral formulations, external preparations, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. It can be formulated in the form of suppositories and sterile injectable solutions.
  • Carriers, excipients and diluents that may be included in the composition comprising the compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. Are mixed to prepare.
  • lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • Uittepsol, macrogol, Tween 60, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • Preferred dosages of the compounds of the present invention depend on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, but may be appropriately selected by those skilled in the art.
  • the compound of the present invention is preferably administered at 0.1 to 1000 mg / kg, preferably 1 to 100 mg / kg. Administration may be administered once a day or may be divided orally.
  • the dosage does not limit the scope of the invention in any aspect.
  • the functional food of the present invention includes various foods, candy, chocolate, beverages, gums, teas, vitamin complexes, health supplements, and the like, and can be used in the form of powders, granules, tablets, capsules or beverages.
  • the compounds of the present invention or their food acceptable salts can be added to food or beverages for the purpose of preventing brain cancer or improving brain cancer conditions.
  • the amount of the compound in the food or beverage is generally added to the dietary supplement composition of the present invention to 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight, the health beverage composition is 100 ml It can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g as a reference.
  • the health beverage composition of the present invention has no particular limitation on the liquid component except for containing the compound of the present invention as an essential ingredient in the indicated proportions, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates are monosaccharides such as glucose, fructose and the like, disaccharides such as maltose, sucrose and the like, conventional sugars such as polysaccharides such as dextrin, cyclodextrin and xylitol Sugar alcohols such as sorbitol and erythritol.
  • natural flavoring agents such as sorbitol and erythritol.
  • the functional food of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors.
  • Flavoring agents, coloring and neutralizing agents such as cheese and chocolate
  • pectic acid and salts thereof alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonated drinks Carbonic acid used, etc.
  • the functional food of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. It may be used either individually or in combination. It is common ratio of the additive is selected from the range of the composition per 100 parts by weight 0 to about 20 parts by weight of the present invention, but not so important.
  • the Stereocaulon alpinum (Hedw. GL Sm.) was introduced in January 2003 at the Barton Peninsular around King Sejong Station (S 62 ° 13.3 ', W58 ° 47.0') in King George Island, Antarctica.
  • the lichens can be easily collected from Barton Peninsula.
  • Example 1-1 204.6 mg of the fraction obtained by elution with 80% methanol obtained in Example 1-1 was again subjected to sample injection into flash column chromatography (2.5 ⁇ 30 cm) filled with silica gel (C 18 ), followed by TLC analysis. 200 ml of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% and 10% methanol and methyl chloride, respectively, to obtain the eight major fractions obtained by Solution and 100% (v / v) methanol were injected to give each fraction.
  • Example 2 Test of anticancer effect of lovastin's T98G cell line, the temozolomide resistant polymorphic glioblastoma cell line 1
  • the lovastin powder a compound of Formula 1 synthesized in Example 1, was completely dissolved by reconstitution at 100 mM concentration in DMSO (dimethylsulfoxide) solution, and then aliquoted and stored at -70 ° C.
  • DMSO dimethylsulfoxide
  • Human GBM cell lines were purchased from the American Type Culture Collection (Manassas, VA). Cell lines were maintained in a 37 ° C. humidified cell culture medium containing 10% FBS (fetal bovine serum; Welgene) in Dulbecco's modified Eagle's medium (DMEM; Welgene) and 5% CO 2 .
  • FBS fetal bovine serum
  • DMEM Dulbecco's modified Eagle's medium
  • Example 2-2 One day prior to drug treatment, the cells of Example 2-2 were cultured by dispensing at a concentration of 1 ⁇ 10 6 cells per 100 mm culture dish (about 55 cm 2). When the cells reached 40-50% confluency the next day, the drug (Lovastin solution of Example 2-1) was diluted to an appropriate concentration in the medium and treated for 3 or 4 days. DMSO, a solvent, was used as a negative control, and temozolomide, an anticancer agent of standard therapy, was treated as a positive control.
  • DMSO a solvent
  • temozolomide an anticancer agent of standard therapy
  • cytotoxicity was confirmed using EZ-CyTox cell viability assay kit (Daeil Lab Service, Seoul, Korea).
  • the drug-treated cultured cells and 10 ⁇ l of the EZ-CyTox kit reagent were added to a 96-well microplate and incubated in a 37 ° C humidified cell incubator for 1 hour, and the absorbance at 450 nm was absorbed (A 450 ). Was measured. Survival of the experimental group is calculated by converting A 450 of the negative control to 100%.
  • T98G a GBM cell line resistant to the anticancer drug, temozolomide (TMZ)
  • TMZ temozolomide
  • FIG. 1A Compound Rovastin of the formula (1) of the present invention was found to be remarkable when the toxicity against T98G cell line GBM cell line having TMZ resistance is more than 50 ⁇ M (Fig. 1B).
  • lovastin according to the present invention can be used alone as an effective drug for the prevention and treatment of brain cancer, but also at low concentrations, especially against brain cancer cell lines having temozolomide resistance, which is currently the only standard therapeutic anticancer agent for brain cancer. Bar suggests that it can be prepared as a drug that can overcome the anticancer drug resistance.
  • Lovastin was synthesized as described in Example 1.
  • Human glioblastoma T98G cells (Dr. SS Kang, D.) supplemented with 10% fetal bovine serum (JR Scientific, USA), 100 units / ml penicillin and 100 ⁇ g / ml streptomycin sulfate (Welljin, Korea) Gyeongsang National University, Korea) and primary human fibroblasts (Dr. JH Lee, Chungnam National University, Korea) were cultured.
  • Lovastin was administered to T98G glioblastoma cells in various amounts for 3 days.
  • the T98G cell line was divided into four groups and treated with high concentrations of TMZ (750 ⁇ M) or the compound lovastin (40 ⁇ M) of Formula 1 alone or in combination (Robarstin + TMZ) for 3 days and 4 days.
  • Solvent DMSO was used.
  • Lovastin was used at a concentration of 40 ⁇ M or less with a concentration of 50 ⁇ M or less confirming the remarkable effect confirmed in Example 2.
  • T98G cell line was further divided into four groups and treated with low concentrations of TMZ (500 ⁇ M) or Compound 1 lovastin (40 ⁇ M) alone or in combination (Robarstin + TMZ) for 3 and 4 days.
  • TMZ 500 ⁇ M
  • Compound 1 lovastin 40 ⁇ M
  • Robotstin + TMZ 3 and 4 days.
  • DMSO a solvent
  • RT-PCR Reverse transcription-polymerase chain reaction
  • RT-PCR was performed (S. Jo et al., Biochem Biophys Res Commun , 416: 86-91, 2011). Briefly, PCR using HiPi Plus Thermostable DNA Polymerase (Elpis Biotech, Korea) followed by total RNA extracted with Solution D was used to make cDNA with M-MLV Reverse Transcriptase (Elpis Biotech, Korea).
  • Primers used for PCR were as follows: MGMT _F, GCAATGAGAGGCAATCCTGT; MGMT _R, GTCGCTCAAACATCCATCCT; GAPDH _F, CTCAGACACCATGGGGAAGGTGA; GAPDH _R, ATGATCTTGAGGCTGTTGTCATA; PARP1- F, GCTCCTGAACAATGCAGACA; PARP1 _R, CATTGTGTGTGGTTGCATGA; LIG3 _F, GTGGATTTGGGCATGTATCC; LIG3_R , GCCCATTCCCCCTATACTGT; XRCC1 _F, GAGGATGAGGCCTCTCACAG; XRCC1 _R, TCCTCTGTGTCCCCAGAATC; MPG _F, TGGCACAGGATGAAGCTGTA; MPG _R, GTGTCCTGCTCAGCCACTCT (PARP1, poly (ADP-ribose) polymerase 1; LIG3,
  • Temozolomide is used as a general chemotherapeutic agent for gliomas, but temozolomide is not associated with patients expressing MGMT, a gene involved in restoring alkylation induced at the O 6 position of guanine by TMZ. In comparison, the effect was small.
  • T98G cells were used because MGMT is known to express these cell lines (FIG. 5). Thus, it was more resistant to TMZ. There was statistically significant toxicity of TMZ under all conditions, but more pronounced at administration of 500 and 750 ⁇ M (FIG. 6).
  • the combination of lovastin with high doses of TMZ resulted in enhanced toxicity (FIG. 7).
  • DNA damage was quantified by gene comet assay. First, the effect of lovastin on DNA damage was investigated. Treatment with only 40 ⁇ M of lovastin for 26 hours showed only minimal effect on DNA damage, indicating that tail strength (TI) is comparable to that of carrier administered cells (compare L and V in FIG. 8). ).
  • T98G cells were administered with 500 ⁇ M of TMZ or lovastin together for 2 hours to investigate the effect on DNA damage. Both showed similar ranges of DNA damage under conditions of 2 hours (comparison of T (D) and LT (D) in FIG. 8), which is sufficient time to cause DNA damage and DNA repair following DNA damage. The time is short enough to prevent the systems from overlapping (A in FIG. 8). Therefore, cells were rinsed 2 hours after drug administration and cultured in fresh culture medium to measure recovery of DNA damage (FIG. 8A). When damaged cells were incubated for 24 hours in fresh medium, cells cultured in lovastin-containing medium showed higher TI than cells administered with a carrier (compare T (R) and LT (R) in FIG. 8). These results indicate that lovastin alone does not induce DNA damage, but that DNA damage induced by TMZ persists in the presence of lovastin.
  • lovastin-administered cells showed more DNA damage, indicating that the DNA repair system is affected by lovastin.
  • Administration of lovastin alone for 2 days to T98G cells resulted in a decrease in the expression of MGMT and PARP1 proteins, related to DNA repair, depending on time (left side of FIG. 9). Reduction in expression was also seen in the translation phase (right side of FIG. 9).
  • the combination of lovastin and TMZ resulted in lower expression of MGMT, PARP1, LIG3 and XRCC1 (FIG. 10).
  • Lobarstin a compound derived from stereocaulon alpinum according to the present invention, has been shown to show cytotoxicity when treated alone with temozolomide-resistant cancer cell lines, and thus can be prepared as a drug that can overcome anticancer drug resistance. Confirmed that it can. In addition, lovastin is confirmed that the cell death is enhanced when co-treatment with the anti-cancer drug temozolomide of the standard therapy, it is also useful to be developed as a combination therapy for the existing therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle utilisation de la lobarstine qui est un métabolite dérivé d'une substance naturelle. Plus particulièrement, la présente invention concerne l'utilisation d'une composition contenant de la lobarstine ou son sel pharmaceutiquement acceptable pour prévenir ou traiter une tumeur cérébrale, et son utilisation en polythérapie, en association avec le témozolomide, pour traiter une tumeur cérébrale. Puisqu'il a été confirmé que la cytotoxicité cellulaire est présentée lorsqu'une lignée de cellules cancéreuses résistante au témozolomide est traitée uniquement avec la lobarstine, qui est un composé selon la présente invention, la présente invention peut être préparée sous la forme d'un médicament pour surmonter la résistance au médicament anticancéreux. En outre, il a été confirmé que la mort cellulaire est favorisée durant une polythérapie utilisant la lobarstine et témozolomide, qui est un médicament anticancéreux utilisé en traitement standard, et il est ainsi possible de développer la présente invention sous la forme d'un médicament pour une polythérapie ajoutée à un traitement classique. Par conséquent, la présente invention est utile.
PCT/KR2013/009366 2012-10-24 2013-10-21 Composition pharmaceutique contenant de la lobarstine pour prévenir ou traiter une tumeur cérébrale et polythérapie pour le traitement d'une tumeur cérébrale l'utilisant Ceased WO2014065545A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120118464A KR101892078B1 (ko) 2012-10-24 2012-10-24 로바스틴을 함유하는 뇌암의 예방 또는 치료용 약학 조성물 및 이를 이용한 뇌암의 치료를 위한 병용요법
KR10-2012-0118464 2012-10-24

Publications (1)

Publication Number Publication Date
WO2014065545A1 true WO2014065545A1 (fr) 2014-05-01

Family

ID=50544875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/009366 Ceased WO2014065545A1 (fr) 2012-10-24 2013-10-21 Composition pharmaceutique contenant de la lobarstine pour prévenir ou traiter une tumeur cérébrale et polythérapie pour le traitement d'une tumeur cérébrale l'utilisant

Country Status (2)

Country Link
KR (1) KR101892078B1 (fr)
WO (1) WO2014065545A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111819170A (zh) * 2017-12-29 2020-10-23 韩国海洋研究院 用于合成肺衣酸及其类似物的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460578B1 (ko) 2020-06-26 2022-10-31 선문대학교 산학협력단 Sr 140333 및 hbc를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102460579B1 (ko) 2020-06-26 2022-10-31 선문대학교 산학협력단 푸라미딘 및 hbc를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102471741B1 (ko) 2020-06-26 2022-11-29 선문대학교 산학협력단 베르바민 및 아르사이리아플라빈 a를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102524954B1 (ko) 2020-06-26 2023-04-24 선문대학교 산학협력단 베르바민 및 l-732,138를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102665137B1 (ko) 2021-08-06 2024-05-13 선문대학교 산학협력단 NK1R을 표적으로 하는 siRNA를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102639035B1 (ko) 2021-08-06 2024-02-21 선문대학교 산학협력단 베르바민 및 아프레피탄트를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102655754B1 (ko) 2021-08-06 2024-04-09 선문대학교 산학협력단 Hbc 및 아프레피탄트를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102655755B1 (ko) 2021-08-06 2024-04-09 선문대학교 산학협력단 Hbc 및 l-732,138을 포함하는 뇌암 치료, 개선 또는 예방용 조성물
KR102639036B1 (ko) 2021-08-06 2024-02-21 선문대학교 산학협력단 베르바민 및 sr 140333을 포함하는 뇌암 치료, 개선 또는 예방용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032544A1 (en) * 2004-02-02 2007-02-08 Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20100184852A1 (en) * 2006-08-11 2010-07-22 Antoine De Saizieu Organic compounds for treatment of disorders connected to impaired neurotransmission
WO2011127589A1 (fr) * 2010-04-15 2011-10-20 National Research Council Of Canada Gènes et protéines servant à la synthèse de polycétides aromatiques
WO2012046945A2 (fr) * 2010-10-07 2012-04-12 한국해양연구원 Composition pharmaceutique et alimentaire pour la prévention ou le traitement du diabète ou de l'obésité

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032544A1 (en) * 2004-02-02 2007-02-08 Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20100184852A1 (en) * 2006-08-11 2010-07-22 Antoine De Saizieu Organic compounds for treatment of disorders connected to impaired neurotransmission
WO2011127589A1 (fr) * 2010-04-15 2011-10-20 National Research Council Of Canada Gènes et protéines servant à la synthèse de polycétides aromatiques
WO2012046945A2 (fr) * 2010-10-07 2012-04-12 한국해양연구원 Composition pharmaceutique et alimentaire pour la prévention ou le traitement du diabète ou de l'obésité

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEO, C. ET AL.: "Protein tyrosine phosphatase 1B inhibitory effects of depsidone and pseudodepsidone metabolites from the Antarctic lichen Stereocaulon alpinum", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 2801 - 2803 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111819170A (zh) * 2017-12-29 2020-10-23 韩国海洋研究院 用于合成肺衣酸及其类似物的方法
CN111819170B (zh) * 2017-12-29 2023-12-29 韩国海洋研究院 用于合成肺衣酸及其类似物的方法

Also Published As

Publication number Publication date
KR20140052396A (ko) 2014-05-07
KR101892078B1 (ko) 2018-08-28

Similar Documents

Publication Publication Date Title
WO2014065545A1 (fr) Composition pharmaceutique contenant de la lobarstine pour prévenir ou traiter une tumeur cérébrale et polythérapie pour le traitement d'une tumeur cérébrale l'utilisant
WO2023214716A1 (fr) Composition pharmaceutique et aliment fonctionnel de santé pour la prévention de l'obésité comprenant un extrait de garcinia cambogia
US20240016765A1 (en) Use of an alkaloid compound in the preparation of products for the prevention and/or treatment of cardiac damage
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2017026641A1 (fr) Composition destinée à prévenir ou traiter le cancer du col de l'utérus et contenant du gypenoside lxxv
WO2018106002A1 (fr) Composition pour la prévention et le traitement de la stérilité masculine, contenant une combinaison de composés comprenant un dérivé de flavonoïde et un dérivé d'iridoïde à titre de principe actif, et son utilisation
KR20110039831A (ko) 염주괴불주머니 유래 쿠마린계 화합물, 및 이를 함유하는 항암용 조성물
US8227512B2 (en) Pharmaceutical composition containing daurinol for the prevention and treatment of cancers
JP6651498B2 (ja) Ｇｌｅｃｈｏｍａ ｌｏｎｇｉｔｕｂａ （Ｎａｋａｉ） Ｋｕｐｒ．抽出物、その調製方法および血糖の低下、体重の減量または血液脂質の低下におけるその使用
WO2014051359A1 (fr) Composition pharmaceutique comprenant de la néférine comme ingrédient actif de prévention contre un hépatome ou de traitement de ce dernier
KR101060942B1 (ko) 리코찰콘 ａ의 신규 용도
KR101481140B1 (ko) 신규 화합물 로바린을 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물
WO2024048998A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'une maladie osseuse, contenant de l'acide salvianolique en tant que principe actif
KR101481141B1 (ko) 신규 화합물 로바스틴을 함유하는 당뇨병 예방 또는 치료용 약학 조성물
WO2021187905A1 (fr) Composition pharmaceutique pour le traitement du cancer et du cancer résistant comprenant trichosanthes kirilowii maxim, dictamnus dasycarpus turcz et morus alba l.
WO2020060264A1 (fr) Composition comprenant un dérivé de sulforaphane pour la prévention, le traitement ou le soulagement de l'atrophie musculaire et de la sarcopénie
WO2024215117A1 (fr) Procédé de préparation d'extrait d'anemone raddeana contenant une concentration élevée de saponines anticancéreuses
CN115089576B (zh) 木犀草素和菊苣酸联合在制备乳腺癌治疗药物中的应用
LU501676B1 (en) Application of alkaloid compound hip in treatment of cardiac trauma
WO2024080420A1 (fr) Composition pour la prévention et le traitement du cancer du foie contenant du ginsénoside rh2 et du ginsénoside rg5 en tant que principes actifs
KR101514145B1 (ko) 마카에리움 쿠스피다툼 추출물을 유효성분으로 포함하는 항암 조성물
WO2017222252A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer du côlon, contenant un extrait de telectadium dongnaiense comme principe actif
WO2023096326A1 (fr) Composition comprenant lgk974 pour prévenir ou traiter une maladie rénale inflammatoire
KR101523434B1 (ko) 줄베르나디아 글로비플로라 추출물을 유효성분으로 포함하는 항암 조성물
KR101675642B1 (ko) 카르피너스 푸베센스 추출물을 포함하는 항암 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13848644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28.08.2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13848644

Country of ref document: EP

Kind code of ref document: A1